Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.

about

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.

Item

http://www.wikidata.org/entity/Q54119060

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Erlotinib treatment after plat ...... sults from the ElderTac study.

@en

Erlotinib treatment after plat ...... sults from the ElderTac study.

@nl

type

Item

label

Erlotinib treatment after plat ...... sults from the ElderTac study.

@en

Erlotinib treatment after plat ...... sults from the ElderTac study.

@nl

prefLabel

Erlotinib treatment after plat ...... sults from the ElderTac study.

@en

Erlotinib treatment after plat ...... sults from the ElderTac study.

@nl

P1476

Erlotinib treatment after plat ...... sults from the ElderTac study.

@en

P2093

H Jost Achenbach

http://www.w3.org/2001/XMLSchema#string

Joachim H Ficker

http://www.w3.org/2001/XMLSchema#string

Wolfgang M Brueckl

http://www.w3.org/2001/XMLSchema#string

Wolfgang Schuette

http://www.w3.org/2001/XMLSchema#string

P2860

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Global cancer statistics, 2012

Untangling the ErbB signalling network

Comprehensive genomic characterization of squamous cell lung cancers.

Erlotinib in previously treated non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.

P2888

s12885-018-4208-x

P304

333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4208-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101779742

http://www.w3.org/2001/XMLSchema#string

P698

29587656

http://www.w3.org/2001/XMLSchema#string

P932

5870245

http://www.w3.org/2001/XMLSchema#string